Pfizer Inc and its German partner BioNTech SE say they expect their experimental coronavirus vaccine to be ready to seek regulatory approval by the end of the year. SE co-founder and CEO Dr Ugur Sahin told The Wall Street Journal the company hopes to produce millions of doses before approval, and more than one billion by the end of 2021. Pfizer and its German partner BioNTech SE are entering large-scale human trials this summer for their coronavirus vaccine. Pictured: Pfizer headquarters in New York City'It is in the nature of innovation to take center stage at a time of great urgency,' Dr Sahin told The Journal. For the study, three groups of 12 received either a 10-microgram dose, a 30-microgram dose or a 100-microgram dose.

Source: Daily Mail July 10, 2020 17:57 UTC